Article
Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation.
Journal of cancer research and clinical oncology - 1 May 2021
Keller Brian A, Laight Brian J, Varette Oliver, Broom Aron, Wedge Marie-Ève, McSweeney Benjamin, Cemeus Catia, Petryk Julia, Lo Bryan, Burns Bruce, Nessim Carolyn, Ong Michael, Chica Roberto A, Atkins Harold L, Diallo Jean-Simon, Ilkow Carolina S, Bell John C
Abstract excerpt
PURPOSE: Mutations in BRAF are the most prominent activating mutations in melanoma and are increasingly recognized in other cancers. There is currently no accepted treatment regimen for patients with mutant BRAFK601N melanoma, and the study of melanoma driven by BRAF mutations at the 601 locus is lacking due to a paucity of cellular model systems. Therefore, we sought to better understand the treatment and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.